Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients
Phase of Trial: Phase IV
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Jan 2018 Planned End Date changed from 12 Apr 2023 to 30 Sep 2020.